This research identifies antifungal alteramide C in Lysobacter sp., demonstrating its effectiveness against soybean anthracnose, suggesting novel biocontrol strategies.
Soybean anthracnose, caused by the fungus Colletotrichum truncatum, poses a serious threat to global soybean production. In this study, we isolated and characterized Lysobacter sp. strain SR01, a novel bacterium that exhibits strong antagonistic activity against C. truncatum. Combined chemical and genomic analyses identified alteramide C and its precursor, 3-deOH alteramide C, as the key antifungal metabolites. These compounds are biosynthesized by a PoTeM-type atc gene cluster, which notably lacks the cyclase genes OX1 and OX4 required for the canonical heat-stable antifungal factor pathway. The heterologous expression of OX4 in SR01 redirected metabolite production toward HSAF-type scaffolds, demonstrating the genetic plasticity of the cluster. Purified alteramide C and 3-deOH alteramide C strongly inhibited mycelial growth and conidial germination in vitro and significantly reduced lesion development on soybean pods under both protective and curative conditions. Our findings reveal a lineage-specific metabolic shortcut that generates structurally simplified antifungal compounds, reflecting an evolutionary adaptation for efficient biosynthesis through a truncated pathway, and highlight the potential of these simplified molecules as sustainable candidates for the control of soybean anthracnose.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: